MAPT and Mental deterioration: On the contrary, recent studies have shown the association between higher levels of plasma GFAP and increased risk of clinical progression and steeper rates of cognitive decline (even after adjusting for amyloid) (Rajan et al, 2020; Verberk et al, 2021; Ebenau et al, 2022), which supports a link with tau pathology given the known strong association between tau and clinical symptoms.